LONDON, July 10, 2017 /PRNewswire/ -- This report analyzes the worldwide markets for Human Growth Hormone Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Download the full report: https://www.reportbuyer.com/product/4707131/Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 28 companies including many key and niche players such as:- Eli Lilly and Company- Ferring Holding SA- Genentech, Inc.- GeneScience Pharmaceuticals Co., Ltd.- Merck KgaADownload the full report: https://www.reportbuyer.com/product/4707131/I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting LimitationsDisclaimersData Interpretation & Reporting LevelQuantitative Techniques & AnalyticsProduct Definitions and Scope of StudyII. EXECUTIVE SUMMARY1. INDUSTRY OVERVIEWMarket OutlookEvolution of Recombinant Human Growth Hormones (hGH)List of Select Approved Prescription Daily-dose hGH Products by IndicationPatent Expiry Paves Way for the Emergence of Biosimilars; Impact Remains SmallStrong Innovation Drive Takes Hold of the hGH IndustrySizing the MarketKey Growth DriversHigh Prevalence of Growth Hormone Deficiency DisordersInnovations Hold the Key to Market GrowthNew Indications for hGH Replacement TherapyMajor Growth Restraining FactorsComplex Delivery SystemHigh Cost of hGH TreatmentDifficulty in Securing ReimbursementBiosimilars Threaten Revenue Growth ErosionLimited Pharmacological Differences Exist Among Current Agents2. MARKET TRENDS & ISSUESPediatric GHD Rules, while Adult GHD Remains UnderservedTable 1: Worldwide Recombinant Human Growth Hormone Market by Indication (2016E): Percentage Breakdown of Value Sales for Adult GHD, Turner Syndrome & Idiopathic Short Stature; Pediatric GHD; and Others (includes corresponding Graph/Chart)Long-Acting hGH Drugs - a Potential Game ChangerSelect Long-Acting hGH Products in Pipeline by Development StageBiosimilars Create Little Impact, Further Validation to Expand Indications and GrowthTable 2: Worldwide Biosimilar Demand by Product Category (2013): Percentage Breakdown of Value Sales for Epoetina, Granulocyte Colony-Stimulating Factors (G-CSFs), Interferons, Insulins, Low Molecular Weight Heparins (LMWH), Recombinant Human Growth Hormones (rhGHs), and Others (includes corresponding Graph/Chart)Manufacturers Bet on Novel Drug Delivery TechnologiesPhase IV Studies Necessitated for First BiosimilarsNeedle-less Drug Delivery Systems to Wipe Out of SyringesDrug Delivery Device Options for Marketed hGH ProductsGrowing Non-Prescription/Off-Label Usage - A Potential Health HazardOral hGH Secretagogues - An Alternative to Controversial hGH Injections in Professional SportsRisk of Cancer Necessitates Judicious Use of hGH in ChildrenDose Titration - A Key to Achieve Enhanced TolerabilityGrowth Concerns about Prolonged Usage of Growth Hormones3. COMPETITIVE LANDSCAPEhGH - A Highly Consolidated MarketTable 3: Leading Recombinant hGH Products in the Global Market (2015): Annual Sales in US$ Million for Genotropin, Humatrope, Norditropin, Nutropin and Saizen (includes corresponding Graph/Chart)Overview of Select Leading Marketed hGH ProductsNorditropinGenotropinHumatropeSaizenOmnitrope - the Somatropin BiosimilarSomatropin BiopartnersReview of Select hGH Products in PipelineOPKO's Lagova to be the Earliest of Long-Acting hGHs to Hit the MarketSomavaratan Advances Further in Clinical TrialsSomapacitan Moves Ahead in Development; Nears Commercial LaunchTransCon hGH - the Potential Blockbuster hGH Product in WaitingHanAll's Vitatropin4. HUMAN GROWTH HORMONE: AN OVERVIEWKey Factors Controlling Natural hGH SecretionStructure of hGHFunctions Performed by hGH in the Human BodyBenefits of Adequate hGHEffects of Human Growth Hormone ImbalancesHypopituitarismEvolution of Growth Hormone Replacement TherapyIndications for Exogenous hGH AdministrationGrowth Hormone Deficiency (GHD)Symptoms of Adult Growth Hormone DeficiencyIdiopathic Short StatureNoonan SyndromePrader-Willi SyndromeTurner SyndromeShort Stature Homeobox GeneSmall for Gestational AgeChronic Renal InsufficiencyShort Bowel SyndromeOther Medical ConditionsOff-label ApplicationsContraindications for Somatropin TherapySafety Review of hGH TherapyReported Adverse Effects of Inaccurate rhGH DosagesRisks Involved with Pediatric/Adolescent hGH Replacement TherapyRisks Involved with Adult hGH Replacement Therapy5. RECENT INDUSTRY ACTIVITYNHI Includes JCR Pharmaceuticals's GROWJECT Liquid hGH Formulations in Reimbursement ListingAscendis Pharma Commences Phase III Trial on TransCon hGHTeijin Inks License Deal with Versartis for SomavaratanJCR Pharmaceuticals Obtains Japanese MHLW Approval for Growject® Liquid FormulationsMerck Dissolves Merck Serono and Merck Millipore Brands, Relaunches Merck BrandEMD Serono and Aeterna Zentaris Finalize Promotional Services Deal for SaizenVersartis Commences Phase II/III Studies for VRS-317 in JapanFerring Pharmaceuticals Obtains FDA Clearance for Name Change of Growth HormoneHanmi Introduces Development-Stage Long Acting hGHNovo Nordisk Obtains FDA Approval for Norditropin® FlexPro® Prefilled PenOPKO and Pfizer Ink Agreement for Development of OPKO's Long- acting hGH-CTPPfizer Announces Positive Results from Phase 3B Study on Genotropin for SGA in Children6. FOCUS ON SELECT GLOBAL PLAYERSEli Lilly and Company (US)Ferring Holding SA (Switzerland)Genentech, Inc. (US)GeneScience Pharmaceuticals Co., Ltd. (China)Merck KgaA (Germany)Novo Nordisk A/S (Denmark)Pfizer, Inc. (US)Sandoz International GmbH (Germany)7. GLOBAL MARKET PERSPECTIVETable 4: World Recent Past, Current and Future Analysis for Human Growth Hormone Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 5: World Historic Analysis for Human Growth Hormone Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)Table 6: World 14-Year Perspective for Human Growth Hormone Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)III. MARKET1. THE UNITED STATESA.Market AnalysisCurrent & Future AnalysisUS hGH Market - A Peek into GHD Prevalence and Cost of TreatmentTable 7: US Patient Volumes Receiving Growth Hormone Therapy by Indication (2016E): Breakdown of Number of Patients in Thousands for Adult GHD, Pediatric GHD and Other Indications (includes corresponding Graph/Chart)Table 8: US hGH Market by Indication (2016E): Percentage Breakdown of Value Sales for Adult GHD, Idiopathic Short Stature, Pediatric GHD, Turner Syndrome and Others (includes corresponding Graph/Chart)FDA Approvals Clear Way for Treating More ChildrenMajor hGH Drugs Available in the US, and FDA Approved IndicationsUS FDA Promotes rhGH Development through Orphan Drug DesignationFDA Approval of First BiosimilarOmnitrope Versus Genotropin - A US PerspectiveFDA Issues First Draft of Guidelines for Biosimilar and Interchangeable BiologicalsFDA Regulations Governing hGH Products in the OTC Drugs MarketAlarming Increase in Sales of hGH Drugs for Anti-Ageing TherapyStrategic Corporate DevelopmentsSelect Key PlayersB.Market AnalyticsTable 9: The US Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 10: The US Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)2. CANADAMarket AnalysisTable 11: Canadian Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 12: Canadian Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)3. JAPANA.Market AnalysisCurrent & Future AnalysisMarket OverviewTable 13: Japanese Patient Volumes Receiving Growth Hormone Therapy by Indication (2016E): Breakdown of Number of Patients in Thousands for Adult GHD, Pediatric GHD and Other Indications (includes corresponding Graph/Chart)Table 14: Japanese hGH Market by Indication (2016E): Percentage Breakdown of Value Sales for Pediatric GHD and Others (includes corresponding Graph/Chart)Competition in the Japanese hGH MarketTable 15: Key Players in the Japanese hGH Market (2012, 2014 & 2016): Percentage Breakdown of Value Sales for Eli Lilly, JCR, Novo Nordisk, Pfizer and Others (includes corresponding Graph/Chart)Timeline of Major Approvals for JCR Pharmaceutical's hGH Product GrowjectJapanese Biosimilar Regulatory GuidelinesSandoz' Omnitrope - the First Biosimilar hGH Launched in JapanStrategic Corporate DevelopmentsB.Market AnalyticsTable 16: Japanese Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 17: Japanese Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4. EUROPEA.Market AnalysisCurrent & Future AnalysisPediatric GHD - Leading Target Indication for hGH ProductsTable 18: European Patient Volumes Receiving Growth Hormone Therapy by Indication (2016E): Breakdown of Number of Patients in Thousands for Adult GHD, Pediatric GHD and Other Indications (includes corresponding Graph/Chart)Table 19: European hGH Market by Indication (2016E): Percentage Breakdown of Value Sales for Adult GHD, Pediatric GHD and Others (includes corresponding Graph/Chart)European hGH Market Focuses on Product Differentiation to Revitalize SalesRegulations Pertaining to Biosimilars in the EUTable 20: Adoption Rates for hGH Biosimilar in Major Western Europe Markets: 2016 (includes corresponding Graph/Chart)New Indications Could Drive GrowthB.Market AnalyticsTable 21: European Recent Past, Current and Future Analysis for Human Growth Hormone Drugs by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 22: European Historic Analysis for Human Growth Hormone Drugs by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)Table 23: European 14-Year Perspective for Human Growth Hormone Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)4a. FRANCEMarket AnalysisTable 24: French Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 25: French Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4b. GERMANYA.Market AnalysisCurrent & Future AnalysisStrategic Corporate DevelopmentKey PlayersB.Market AnalyticsTable 26: German Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 27: German Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4c. ITALYMarket AnalysisTable 28: Italian Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 29: Italian Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4d. THE UNITED KINGDOMMarket AnalysisTable 30: The UK Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 31: The UK Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4e. SPAINMarket AnalysisTable 32: Spanish Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 33: Spanish Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4f. REST OF EUROPEA.Market AnalysisCurrent & Future AnalysisStrategic Corporate DevelopmentSelect Key PlayersB.Market AnalyticsTable 34: Rest of Europe Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 35: Rest of Europe Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)5. ASIA-PACIFICA.Market AnalysisCurrent & Future AnalysisBiosimilar Regulations In Asian CountriesSouth KoreaChinaIndiaGenescience Pharmaceuticals Co., Ltd. - A Leading Chinese PlayerB.Market AnalyticsTable 36: Asia-Pacific Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 37: Asia-Pacific Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)6. REST OF WORLDMarket AnalysisTable 38: Rest of World Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)Table 39: Rest of World Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)IV. COMPETITIVE LANDSCAPETotal Companies Profiled: 28 (including Divisions/Subsidiaries - 33) The United States (10) Canada (1) Japan (2) Europe (10) - Germany (4) - The United Kingdom (2) - Rest of Europe (4) Asia-Pacific (Excluding Japan) (9) Middle East (1)Download the full report: https://www.reportbuyer.com/product/4707131/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.comFor more information: Sarah Smith
Research Advisor at Reportbuyer.com Email: [email protected]
Tel: +44 208 816 85 48 Website: www.reportbuyer.com
View original content:http://www.prnewswire.com/news-releases/global-human-growth-hormone-drugs---pharmaceuticals-300485532.html
SOURCE ReportBuyer
